{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:07:23Z","timestamp":1793984843655,"version":"4.8.0"},"reference-count":213,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.eururo.2023.04.008","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T04:35:56Z","timestamp":1684298156000},"page":"207-222","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":224,"title":["Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms"],"prefix":"10.1016","volume":"84","author":[{"given":"Stavros","family":"Gravas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Gacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Gratzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas R.W.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markos","family":"Karavitakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iason","family":"Kyriazis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Malde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalampos","family":"Mamoulakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malte","family":"Rieken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasileios I.","family":"Sakalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Schouten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Speakman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari A.O.","family":"Tikkinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Nicolas","family":"Cornu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2023.04.008_b0005","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00345-010-0605-8","article-title":"Prevalence and factors associated with uncomplicated storage and voiding lower urinary tract symptoms in community-dwelling Australian men","volume":"29","author":"Martin","year":"2011","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0010","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.eururo.2014.01.019","article-title":"What is the most bothersome lower urinary tract symptom? Individual- and population-level perspectives for both men and women","volume":"65","author":"Agarwal","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0015","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.1001\/archinte.166.21.2381","article-title":"Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey","volume":"166","author":"Kupelian","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eururo.2023.04.008_b0020","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s11934-996-0006-0","article-title":"The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States","volume":"7","author":"Taub","year":"2006","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.eururo.2023.04.008_b0025","unstructured":"Chapple C, Abrams P, editors. Lower urinary tract symptoms (LUTS): an international consultation on male LUTS. Soci\u00e9t\u00e9 Internationale d\u2019Urologie (SIU); 2013."},{"key":"10.1016\/j.eururo.2023.04.008_b0030","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bju.12728","article-title":"Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis","volume":"115","author":"Gacci","year":"2015","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0035","unstructured":"Cornu JN, et al. Non-neurogenic male lower urinary tract symptoms (LUTS), including benign prostatic obstruction (BPO). EAU guidelines. Presented at the EAU Annual Congress Milan March; 2023; The Netherlands."},{"key":"10.1016\/j.eururo.2023.04.008_b0040","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.eururo.2020.12.019","article-title":"A systematic review of patients' values, preferences, and expectations for the diagnosis and treatment of male lower urinary tract symptoms","volume":"79","author":"Malde","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0045","unstructured":"Gacci M, et al. European Association of Urology guidelines on male urinary incontinence."},{"key":"10.1016\/j.eururo.2023.04.008_b0050","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2023.04.008_b0055","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.eursup.2006.02.005","article-title":"Critical review of guidelines for BPH diagnosis and treatment strategy","volume":"4","author":"Novara","year":"2006","journal-title":"Eur Urol Suppl"},{"key":"10.1016\/j.eururo.2023.04.008_b0060","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/j.juro.2011.01.074","article-title":"Update on AUA guideline on the management of benign prostatic hyperplasia","volume":"185","author":"McVary","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0065","unstructured":"Bosch J, et al. Etiology, patient assessment and predicting outcome from therapy. International Consultation on Urological Diseases male LUTS guideline. 2013."},{"key":"10.1016\/j.eururo.2023.04.008_b0070","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.juro.2011.04.057","article-title":"Methods of developing UWIN, the modified American Urological Association symptom score","volume":"186","author":"Barqawi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0075","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/S0022-5347(17)36966-5","article-title":"The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association","volume":"148","author":"Barry","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0080","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/S0022-5347(05)66926-1","article-title":"Scoring the short form ICSmaleSF questionnaire. International Continence Society","volume":"164","author":"Donovan","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0085","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/0895-4356(92)90205-2","article-title":"Validation of a new quality of life questionnaire for benign prostatic hyperplasia","volume":"45","author":"Epstein","year":"1992","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.eururo.2023.04.008_b0090","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.urology.2006.02.042","article-title":"Symptom assessment tool for overactive bladder syndrome\u2013overactive bladder symptom score","volume":"68","author":"Homma","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0095","doi-asserted-by":"crossref","first-page":"489","DOI":"10.3109\/00365599309182282","article-title":"The value of a new symptom score (DAN-PSS) in diagnosing uro-dynamic infravesical obstruction in BPH","volume":"27","author":"Schou","year":"1993","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.eururo.2023.04.008_b0100","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1111\/j.1442-2042.2008.02121.x","article-title":"Core Lower Urinary Tract Symptom score (CLSS) questionnaire: a reliable tool in the overall assessment of lower urinary tract symptoms","volume":"15","author":"Homma","year":"2008","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0105","unstructured":"FDA. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. Food and Drug Administration; 2009."},{"key":"10.1016\/j.eururo.2023.04.008_b0110","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1590\/s1677-5538.ibju.2018.0496","article-title":"Prospective comparison of the novel Visual Prostate Symptom Score (VPSS) versus the International Prostate Symptom Score (IPSS), and assessment of patient pain perception with regard to transrectal ultrasound guided prostate biopsy","volume":"45","author":"Els","year":"2019","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0115","doi-asserted-by":"crossref","first-page":"123","DOI":"10.4103\/iju.IJU_300_19","article-title":"Can new, improvised Visual Prostate Symptom Score replace the International Prostate Symptom Score? Indian perspective","volume":"36","author":"Sanman","year":"2020","journal-title":"Indian J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0120","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/nau.22219","article-title":"Nocturia Think Tank: focus on nocturnal polyuria: ICI-RS 2011","volume":"31","author":"Weiss","year":"2012","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2023.04.008_b0125","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1016\/S0022-5347(05)00312-5","article-title":"Nocturia: \u201cdo the math\u201d","volume":"175","author":"Weiss","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0130","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.eururo.2012.07.004","article-title":"A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management\u2013a systematic review and meta-analysis","volume":"62","author":"Cornu","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0135","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/nau.20994","article-title":"Urinary diaries: evidence for the development and validation of diary content, format, and duration","volume":"30","author":"Bright","year":"2011","journal-title":"Neurourol Urodyn"},{"key":"10.1016\/j.eururo.2023.04.008_b0140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1464-410X.2006.06499.x","article-title":"A systematic review of the reliability of frequency-volume charts in urological research and its implications for the optimum chart duration","volume":"99","author":"Yap","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0145","doi-asserted-by":"crossref","first-page":"390S","DOI":"10.1016\/S0197-2456(00)00094-5","article-title":"Quality control of cancer screening examination procedures in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial","volume":"21","author":"Weissfeld","year":"2000","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.eururo.2023.04.008_b0150","first-page":"19","article-title":"Accurate determination of prostate size via digital rectal examination and transrectal ultrasound","volume":"51","author":"Roehrborn","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0155","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eururo.2012.08.011","article-title":"ICUD-EAU International Consultation on Bladder Cancer 2012: urothelial carcinoma of the prostate","volume":"63","author":"Palou","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0160","unstructured":"Bonkat G, et al. EAU guidelines on urological infections. Presented at EAU Annual Congress, Milan, 2021. 2021."},{"key":"10.1016\/j.eururo.2023.04.008_b0165","unstructured":"Babjuk M, et al. EAU guidelines on non-muscle-invasive bladder cancer. Presented at EAU Annual Congress, Milan, Italy; 2021. p. 63."},{"key":"10.1016\/j.eururo.2023.04.008_b0170","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa030656","article-title":"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia","volume":"349","author":"McConnell","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.04.008_b0175","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0022-5347(05)67962-1","article-title":"Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study","volume":"163","author":"Roehrborn","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0180","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1464-410X.2006.06110.x","article-title":"Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study","volume":"97","author":"Roehrborn","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0185","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.urology.2013.07.049","article-title":"Relationship of estimated glomerular filtration rate with lower urinary tract symptoms\/benign prostatic hyperplasia measures in middle-aged men with moderate to severe lower urinary tract symptoms","volume":"82","author":"Lee","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0190","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1111\/j.1464-410X.2009.08975.x","article-title":"Chronic kidney disease among men with lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"105","author":"Hong","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0195","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0022-5347(17)40731-2","article-title":"Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3,885 patients","volume":"141","author":"Mebust","year":"1989","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0200","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.eururo.2006.12.023","article-title":"Diagnostic accuracy of noninvasive tests to evaluate bladder outlet obstruction in men: detrusor wall thickness, uroflowmetry, postvoid residual urine, and prostate volume","volume":"52","author":"Oelke","year":"2007","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0205","doi-asserted-by":"crossref","unstructured":"Rule AD, et al. Longitudinal changes in post-void residual and voided volume among community dwelling men. J Urol 2005;174:1317\u201321; discussion 1321\u20132; author reply 1322.","DOI":"10.1097\/01.ju.0000173922.29275.54"},{"key":"10.1016\/j.eururo.2023.04.008_b0210","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S0022-5347(17)55859-0","article-title":"The flow rate nomogram: II. Clinical correlation","volume":"123","author":"Siroky","year":"1980","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0215","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0033-8389(05)70148-2","article-title":"Benign prostatic hyperplasia: clinical overview and value of diagnostic imaging","volume":"38","author":"Grossfeld","year":"2000","journal-title":"Radiol Clin North Am"},{"key":"10.1016\/j.eururo.2023.04.008_b0220","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/j.1464-410X.1992.tb15664.x","article-title":"Is pre-operative imaging of the urinary tract worthwhile in the assessment of prostatism?","volume":"70","author":"Wilkinson","year":"1992","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0225","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0022-5347(01)65691-X","article-title":"The correlation between bladder outlet obstruction and lower urinary tract symptoms as measured by the international prostate symptom score","volume":"156","author":"el Din","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0230","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.urology.2010.05.034","article-title":"Is there a correlation between the presence of idiopathic detrusor overactivity and the degree of bladder outlet obstruction?","volume":"77","author":"Oh","year":"2011","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0235","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eururo.2008.02.017","article-title":"Age and bladder outlet obstruction are independently associated with detrusor overactivity in patients with benign prostatic hyperplasia","volume":"54","author":"Oelke","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0240","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1464-410X.2003.04719.x","article-title":"The natural history of lower urinary tract dysfunction in men: the influence of detrusor underactivity on the outcome after transurethral resection of the prostate with a minimum 10-year urodynamic follow-up","volume":"93","author":"Thomas","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0245","doi-asserted-by":"crossref","first-page":"342","DOI":"10.4111\/kju.2012.53.5.342","article-title":"Prevalence and clinical features of detrusor underactivity among elderly with lower urinary tract symptoms: a comparison between men and women","volume":"53","author":"Jeong","year":"2012","journal-title":"Korean J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0250","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2020.06.004","article-title":"Diagnostic assessment of lower urinary tract symptoms in men considering prostate surgery: a noninferiority randomised controlled trial of urodynamics in 26 hospitals","volume":"78","author":"Drake","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0255","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0022-5347(01)66589-3","article-title":"The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia","volume":"155","author":"Koch","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0260","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.urology.2009.08.049","article-title":"Correlation between prostatic urethral angle and bladder outlet obstruction index in patients with lower urinary tract symptoms","volume":"75","author":"Ku","year":"2010","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0265","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/01.ju.0000139470.58006.dd","article-title":"Noninvasive assessment of bladder contractility in men","volume":"172","author":"McIntosh","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0270","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/S0022-5347(06)00316-8","article-title":"Ultrasound assessment of detrusor thickness in men-can it predict bladder outlet obstruction and replace pressure flow study?","volume":"175","author":"Kessler","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0275","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1046\/j.1464-410X.2003.04088.x","article-title":"Correlation of intravesical prostatic protrusion with bladder outlet obstruction","volume":"91","author":"Chia","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0280","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/S0090-4295(97)00310-5","article-title":"Correlation of presumed circle area ratio with infravesical obstruction in men with lower urinary tract symptoms","volume":"50","author":"Kojima","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0285","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pros.2990170502","article-title":"Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention","volume":"3","author":"Isaacs","year":"1990","journal-title":"Prostate Suppl"},{"key":"10.1016\/j.eururo.2023.04.008_b0290","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0090-4295(00)00747-0","article-title":"The natural history of benign prostatic hyperplasia: what have we learned in the last decade?","volume":"56","author":"Kirby","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0295","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/j.1464-410X.1981.tb03273.x","article-title":"The natural history of untreated \u201cprostatism\u201d","volume":"53","author":"Ball","year":"1981","journal-title":"Br J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0300","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1056\/NEJM199501123320202","article-title":"A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on Transurethral Resection of the Prostate","volume":"332","author":"Wasson","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2023.04.008_b0305","doi-asserted-by":"crossref","unstructured":"Flanigan RC, et al. 5-Year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998;160:12\u20136; discussion 16\u20137.","DOI":"10.1016\/S0022-5347(01)63011-8"},{"key":"10.1016\/j.eururo.2023.04.008_b0310","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0090-4295(98)00475-0","article-title":"Evaluation of patients with bladder outlet obstruction and mild international prostate symptom score followed up by watchful waiting","volume":"53","author":"Netto","year":"1999","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0315","doi-asserted-by":"crossref","unstructured":"Brown CT, et al. Defining the components of a self-management programme for men with uncomplicated lower urinary tract symptoms: a consensus approach. Eur Urol 2004;46:254\u201362; discussion 263.","DOI":"10.1016\/j.eururo.2004.02.008"},{"key":"10.1016\/j.eururo.2023.04.008_b0320","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/bmj.39010.551319.AE","article-title":"Self management for men with lower urinary tract symptoms: randomised controlled trial","volume":"334","author":"Brown","year":"2007","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2023.04.008_b0325","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.urology.2004.07.031","article-title":"State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia","volume":"64","author":"Djavan","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0330","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.urology.2004.08.049","article-title":"Longitudinal study of men with mild symptoms of bladder outlet obstruction treated with watchful waiting for four years","volume":"64","author":"Djavan","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0335","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/sj.pcan.4500267","article-title":"Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms","volume":"1","author":"Michel","year":"1998","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2023.04.008_b0340","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.eururo.2009.09.035","article-title":"The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study","volume":"57","author":"Roehrborn","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0345","doi-asserted-by":"crossref","unstructured":"Roehrborn CG, et al. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008;179:616\u201321; discussion 621.","DOI":"10.1016\/j.juro.2007.09.084"},{"key":"10.1016\/j.eururo.2023.04.008_b0350","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/sj.pcan.4500849","article-title":"Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate","volume":"9","author":"Roehrborn","year":"2006","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2023.04.008_b0355","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0090-4295(01)01344-9","article-title":"Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia","volume":"58","author":"Boyle","year":"2001","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0360","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1111\/j.1742-1241.2008.01880.x","article-title":"A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia","volume":"62","author":"Nickel","year":"2008","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.eururo.2023.04.008_b0365","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.eururo.2010.10.046","article-title":"Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe","volume":"59","author":"Chapple","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0370","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.jcrs.2005.02.027","article-title":"Intraoperative floppy iris syndrome associated with tamsulosin","volume":"31","author":"Chang","year":"2005","journal-title":"J Cataract Refract Surg"},{"key":"10.1016\/j.eururo.2023.04.008_b0375","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.clinthera.2007.01.018","article-title":"A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate","volume":"29","author":"Naslund","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.eururo.2023.04.008_b0380","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1464-410X.2011.10195.x","article-title":"Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS)","volume":"108","author":"Nickel","year":"2011","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0385","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0090-4295(96)00353-6","article-title":"Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials","volume":"48","author":"Boyle","year":"1996","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0390","doi-asserted-by":"crossref","unstructured":"Gittelman M, et al. Dutasteride improves objective and subjective disease measures in men with benign prostatic hyperplasia and modest or severe prostate enlargement. J Urol 2006;176:1045\u201350; discussion 1050.","DOI":"10.1016\/j.juro.2006.04.032"},{"key":"10.1016\/j.eururo.2023.04.008_b0395","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1464-410X.2005.05686.x","article-title":"Long-term sustained improvement in symptoms of benign prostatic hyperplasia with the dual 5alpha-reductase inhibitor dutasteride: results of 4-year studies","volume":"96","author":"Roehrborn","year":"2005","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0400","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJM199802263380901","article-title":"The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group","volume":"338","author":"McConnell","year":"1998","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"10.1016\/j.eururo.2023.04.008_b0405","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1464-410X.2008.07497.x","article-title":"BPH progression: concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE","volume":"101","author":"Roehrborn","year":"2008","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0410","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0090-4295(97)00185-4","article-title":"Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia","volume":"49","author":"Andersen","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0415","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1159\/000474256","article-title":"Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study","volume":"24","author":"Kirby","year":"1993","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0420","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/S0022-5347(01)66894-0","article-title":"Long-term effects of finasteride on invasive urodynamics and symptoms in the treatment of patients with bladder outflow obstruction due to benign prostatic hyperplasia","volume":"154","author":"Tammela","year":"1995","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0425","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.eururo.2006.02.018","article-title":"A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder","volume":"49","author":"Chapple","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0430","doi-asserted-by":"crossref","unstructured":"Dmochowski R, et al. Efficacy and tolerability of tolterodine extended release in male and female patients with overactive bladder. Eur Urol 2007;51:1054\u201364; discussion 1064.","DOI":"10.1016\/j.eururo.2006.10.005"},{"key":"10.1016\/j.eururo.2023.04.008_b0435","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/bju.13882","article-title":"Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study)","volume":"120","author":"Herschorn","year":"2017","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0440","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00345-007-0212-5","article-title":"Safety and efficacy of tolterodine extended release in men with overactive bladder symptoms and presumed non-obstructive benign prostatic hyperplasia","volume":"25","author":"Hofner","year":"2007","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0445","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1111\/j.1464-410X.2006.06068.x","article-title":"Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence","volume":"97","author":"Roehrborn","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0450","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1001\/jama.296.19.2319","article-title":"Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial","volume":"296","author":"Kaplan","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.eururo.2023.04.008_b0455","doi-asserted-by":"crossref","unstructured":"Kaplan SA, et al. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005;174:2273\u20135; discussion 2275\u20136.","DOI":"10.1097\/01.ju.0000181823.33224.a0"},{"key":"10.1016\/j.eururo.2023.04.008_b0460","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3109\/13685530903440408","article-title":"Solifenacin treatment in men with overactive bladder: effects on symptoms and patient-reported outcomes","volume":"13","author":"Kaplan","year":"2010","journal-title":"Aging Male"},{"key":"10.1016\/j.eururo.2023.04.008_b0465","doi-asserted-by":"crossref","unstructured":"Roehrborn CG, et al. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB. Urology 2008;72:1061\u20137; discussion 1067.","DOI":"10.1016\/j.urology.2008.06.067"},{"key":"10.1016\/j.eururo.2023.04.008_b0470","doi-asserted-by":"crossref","unstructured":"Abrams P, et al. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006;175:999\u20131004; discussion 1004.","DOI":"10.1016\/S0022-5347(05)00483-0"},{"key":"10.1016\/j.eururo.2023.04.008_b0475","first-page":"728","article-title":"Comparing adherence and persistence across 6 chronic medication classes","volume":"15","author":"Yeaw","year":"2009","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.eururo.2023.04.008_b0480","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/iju.13498","article-title":"Systematic review and meta-analysis on the efficacy and tolerability of mirabegron for the treatment of storage lower urinary tract symptoms\/overactive bladder: comparison with placebo and tolterodine","volume":"25","author":"Sebastianelli","year":"2018","journal-title":"Int J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0485","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/ggi.13465","article-title":"Safety and therapeutic efficacy of mirabegron 25 mg in older patients with overactive bladder and multiple comorbidities","volume":"18","author":"Lee","year":"2018","journal-title":"Geriatr Gerontol Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0490","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jash.2018.08.001","article-title":"Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome","volume":"12","author":"White","year":"2018","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.eururo.2023.04.008_b0495","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.eururo.2012.10.048","article-title":"Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a beta(3)-adrenoceptor agonist, in overactive bladder","volume":"63","author":"Chapple","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0500","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.urology.2013.02.077","article-title":"A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the beta(3) adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder","volume":"82","author":"Herschorn","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0505","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.eururo.2012.10.016","article-title":"Efficacy and tolerability of mirabegron, a beta(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial","volume":"63","author":"Khullar","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0510","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.juro.2012.10.017","article-title":"Results of a randomized phase III trial of mirabegron in patients with overactive bladder","volume":"189","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0515","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.juro.2013.05.062","article-title":"Urodynamics and safety of the beta(3)-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction","volume":"190","author":"Nitti","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0520","doi-asserted-by":"crossref","first-page":"e923179","DOI":"10.12659\/MSM.923179","article-title":"Comparative effectiveness of tadalafil versus tamsulosin in treating lower urinary tract symptoms suggestive of benign prostate hyperplasia: a meta-analysis of randomized controlled trials","volume":"26","author":"Guo","year":"2020","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.eururo.2023.04.008_b0525","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.eururo.2012.02.033","article-title":"A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"61","author":"Gacci","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0530","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/luts.12144","article-title":"Tadalafil 5 mg once daily improves lower urinary tract symptoms and erectile dysfunction: a systematic review and meta-analysis","volume":"10","author":"Wang","year":"2018","journal-title":"Low Urin Tract Symptoms"},{"key":"10.1016\/j.eururo.2023.04.008_b0535","unstructured":"European Medicines Agency. Tadalafil Lilly: EPAR\u2014product information. European Medicines Agency; 2017."},{"key":"10.1016\/j.eururo.2023.04.008_b0540","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.pcan.4500746","article-title":"Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract","volume":"7","author":"Habib","year":"2004","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2023.04.008_b0545","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000161128","article-title":"Comparison of the potency of different brands of Serenoa repens extract on 5alpha-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells","volume":"82","author":"Scaglione","year":"2008","journal-title":"Pharmacology"},{"key":"10.1016\/j.eururo.2023.04.008_b0550","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.euf.2016.04.002","article-title":"Efficacy and safety of hexanic lipidosterolic extract of Serenoa repens (Permixon) in the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials","volume":"2","author":"Novara","year":"2016","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2023.04.008_b0555","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1111\/bju.14362","volume":"122","author":"Vela-Navarrete","year":"2018","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0560","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003495-200969030-00008","article-title":"Transdermal oxybutynin","volume":"69","author":"Baldwin","year":"2009","journal-title":"Drugs"},{"key":"10.1016\/j.eururo.2023.04.008_b0565","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11934-015-0531-9","article-title":"Tolterodine in the treatment of male LUTS","volume":"16","author":"Gacci","year":"2015","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.eururo.2023.04.008_b0570","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1097\/01.ju.0000067541.73285.eb","article-title":"Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study","volume":"169","author":"Athanasopoulos","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0575","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2008.11.026","article-title":"Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers","volume":"56","author":"Chapple","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0580","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.juro.2009.08.023","article-title":"Safety and tolerability of solifenacin add-on therapy to alpha-blocker treated men with residual urgency and frequency","volume":"182","author":"Kaplan","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0585","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1464-410X.2004.05039.x","article-title":"Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder","volume":"94","author":"Lee","year":"2004","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0590","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1097\/01.ju.0000173630.94559.fd","volume":"174","author":"Lee","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0595","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.4065\/83.9.1002","article-title":"Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study","volume":"83","author":"MacDiarmid","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.eururo.2023.04.008_b0600","first-page":"525","volume":"12","author":"Saito","year":"1999","journal-title":"Jpn J Urol Surg"},{"key":"10.1016\/j.eururo.2023.04.008_b0605","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/00029330-200703010-00004","article-title":"Efficacy and safety of combined therapy with terazosin and tolterodine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study","volume":"120","author":"Yang","year":"2007","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.eururo.2023.04.008_b0610","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.eururo.2013.07.034","article-title":"Combination therapy with solifenacin and tamsulosin oral controlled absorption system in a single tablet for lower urinary tract symptoms in men: efficacy and safety results from the randomised controlled NEPTUNE trial","volume":"64","author":"van Kerrebroeck","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0615","doi-asserted-by":"crossref","first-page":"e0169248","DOI":"10.1371\/journal.pone.0169248","article-title":"Efficacy and safety of initial combination treatment of an alpha blocker with an anticholinergic medication in benign prostatic hyperplasia patients with lower urinary tract symptoms: updated meta-analysis","volume":"12","author":"Kim","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2023.04.008_b0620","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.eururo.2013.03.031","article-title":"Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN)","volume":"64","author":"Van Kerrebroeck","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0625","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.eururo.2011.03.054","article-title":"The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update","volume":"60","author":"Athanasopoulos","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0630","doi-asserted-by":"crossref","first-page":"e0170726","DOI":"10.1371\/journal.pone.0170726","article-title":"Incidence of urinary retention during treatment with single tablet combinations of solifenacin+tamsulosin OCAS for up to 1 year in adult men with both storage and voiding LUTS: a subanalysis of the NEPTUNE\/NEPTUNE II randomized controlled studies","volume":"12","author":"Drake","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2023.04.008_b0635","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.euf.2019.10.019","article-title":"Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: a randomized, placebo-controlled study (MATCH)","volume":"6","author":"Kakizaki","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2023.04.008_b0640","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1097\/JU.0000000000000738","article-title":"Efficacy and safety of mirabegron versus placebo add-on therapy in men with overactive bladder symptoms receiving tamsulosin for underlying benign prostatic hyperplasia: a randomized, phase 4 study (PLUS)","volume":"203","author":"Kaplan","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0645","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.juro.2014.09.091","article-title":"A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction","volume":"193","author":"Ichihara","year":"2015","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0650","doi-asserted-by":"crossref","first-page":"693","DOI":"10.5414\/CP201979","article-title":"Absence of clinically relevant cardiovascular interaction upon add-on of mirabegron or tamsulosin to an established tamsulosin or mirabegron treatment in healthy middle-aged to elderly men","volume":"52","author":"Van Gelderen","year":"2014","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.eururo.2023.04.008_b0655","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.euf.2019.05.014","article-title":"What is the required certainty of evidence for the implementation of novel techniques for the treatment of benign prostatic obstruction?","volume":"5","author":"Speakman","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2023.04.008_b0660","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.juro.2008.03.058","article-title":"Morbidity, mortality and early outcome of transurethral resection of the prostate: a prospective multicenter evaluation of 10,654 patients","volume":"180","author":"Reich","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0665","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.eururo.2009.06.037","article-title":"Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials","volume":"56","author":"Mamoulakis","year":"2009","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0670","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/bju.12281","article-title":"Systematic review and meta-analysis of the clinical effectiveness of bipolar compared with monopolar transurethral resection of the prostate (TURP)","volume":"113","author":"Omar","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0675","first-page":"CD009629","article-title":"Bipolar versus monopolar transurethral resection of the prostate for lower urinary tract symptoms secondary to benign prostatic obstruction","volume":"2019","author":"Alexander","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2023.04.008_b0680","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/end.2018.0879","article-title":"Safety and effectiveness of bipolar transurethral resection of the prostate in patients under ongoing oral anticoagulation with coumarins or antiplatelet drug therapy compared to patients without anticoagulation\/antiplatelet therapy","volume":"33","author":"Ruhle","year":"2019","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2023.04.008_b0685","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1464-410X.2012.11662.x","article-title":"Bipolar vs monopolar transurethral resection of the prostate: evaluation of the impact on overall sexual function in an international randomized controlled trial setting","volume":"112","author":"Mamoulakis","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0690","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.urology.2016.03.042","article-title":"Holmium laser vs monopolar electrocautery bladder neck incision for prostates less than 30 grams: a prospective randomized trial","volume":"93","author":"Bansal","year":"2016","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0695","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00345-009-0496-8","article-title":"The clinical effectiveness of transurethral incision of the prostate: a systematic review of randomised controlled trials","volume":"28","author":"Lourenco","year":"2010","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0700","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.eururo.2007.08.036","article-title":"Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial","volume":"53","author":"Kuntz","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0705","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.urology.2004.03.033","article-title":"Long-term results of open transvesical prostatectomy from a contemporary series of patients","volume":"64","author":"Varkarakis","year":"2004","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0710","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.juro.2006.11.062","article-title":"Complications and early postoperative outcome after open prostatectomy in patients with benign prostatic enlargement: results of a prospective multicenter study","volume":"177","author":"Gratzke","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0715","doi-asserted-by":"crossref","first-page":"e0121265","DOI":"10.1371\/journal.pone.0121265","article-title":"Endoscopic enucleation versus open prostatectomy for treating large benign prostatic hyperplasia: a meta-analysis of randomized controlled trials","volume":"10","author":"Li","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.eururo.2023.04.008_b0720","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.eururo.2006.04.003","article-title":"Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24-month follow-up","volume":"50","author":"Naspro","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0725","doi-asserted-by":"crossref","unstructured":"Skolarikos A, et al. 80W PVP versus TURP: results of a randomized prospective study at 12 months of follow-up. Abstract presented at American Urological Association annual meeting. Orlando, FL; 2008.","DOI":"10.1016\/S0022-5347(08)61837-6"},{"key":"10.1016\/j.eururo.2023.04.008_b0730","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S0022-5347(05)66102-2","article-title":"A prospective study of the safety and efficacy of suprapubic transvesical prostatectomy in patients with benign prostatic hyperplasia","volume":"166","author":"Tubaro","year":"2001","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0735","doi-asserted-by":"crossref","first-page":"l5919","DOI":"10.1136\/bmj.l5919","article-title":"Comparative efficacy and safety of new surgical treatments for benign prostatic hyperplasia: systematic review and network meta-analysis","volume":"367","author":"Huang","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2023.04.008_b0740","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bju.12181","article-title":"Transurethral enucleation and resection of the prostate vs transvesical prostatectomy for prostate volumes >80 mL: a prospective randomized study","volume":"112","author":"Ou","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0745","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.eururo.2014.01.010","article-title":"Plasmakinetic enucleation of the prostate compared with open prostatectomy for prostates larger than 100 grams: a randomized noninferiority controlled trial with long-term results at 6 years","volume":"66","author":"Chen","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0750","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.urology.2013.02.032","article-title":"Plasmakinetic enucleation of the prostate versus transvesical open prostatectomy for benign prostatic hyperplasia >80 mL: 12-month follow-up results of a randomized clinical trial","volume":"82","author":"Rao","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0755","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1464-410X.2012.11730.x","article-title":"Bipolar plasma enucleation of the prostate vs open prostatectomy in large benign prostatic hyperplasia cases - a medium term, prospective, randomized comparison","volume":"111","author":"Geavlete","year":"2013","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0760","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1089\/end.2014.0493","article-title":"Bipolar vaporization, resection, and enucleation versus open prostatectomy: optimal treatment alternatives in large prostate cases?","volume":"29","author":"Geavlete","year":"2015","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2023.04.008_b0765","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/s41391-019-0135-4","article-title":"Efficacy and safety of enucleation vs. resection of prostate for treatment of benign prostatic hyperplasia: a meta-analysis of randomized controlled trials","volume":"22","author":"Zhang","year":"2019","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2023.04.008_b0770","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s00345-019-02890-9","article-title":"Bipolar endoscopic enucleation versus bipolar transurethral resection of the prostate: an ESUT systematic review and cumulative analysis","volume":"38","author":"Arcaniolo","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0775","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/j.juro.2012.10.117","article-title":"Electrosurgical enucleation versus bipolar transurethral resection for prostates larger than 70 ml: a prospective, randomized trial with 5-year followup","volume":"189","author":"Zhu","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0780","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/bjs.5916","article-title":"Meta-analysis of holmium laser enucleation versus transurethral resection of the prostate for symptomatic prostatic obstruction","volume":"94","author":"Tan","year":"2007","journal-title":"Br J Surg"},{"key":"10.1016\/j.eururo.2023.04.008_b0785","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.eururo.2014.06.017","article-title":"A systematic review and meta-analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic obstruction: an update","volume":"67","author":"Cornu","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0790","doi-asserted-by":"crossref","first-page":"23503","DOI":"10.1038\/srep23503","article-title":"Different lasers in the treatment of benign prostatic hyperplasia: a network meta-analysis","volume":"6","author":"Zhang","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.eururo.2023.04.008_b0795","first-page":"184","article-title":"Functional outcomes and complications following B-TURP versus HoLEP for the treatment of benign prostatic hyperplasia: a review of the literature and meta-analysis","volume":"20","author":"Qian","year":"2017","journal-title":"Aging Male"},{"key":"10.1016\/j.eururo.2023.04.008_b0800","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1464-410X.2011.10359.x","article-title":"Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years","volume":"109","author":"Gilling","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0805","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.juro.2012.08.087","article-title":"A prospective, randomized clinical trial comparing plasmakinetic resection of the prostate with holmium laser enucleation of the prostate based on a 2-year followup","volume":"189","author":"Chen","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0810","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1089\/end.2017.0700","article-title":"Comparison of holmium laser enucleation and plasmakinetic resection of prostate: a randomized trial with 72-month follow-up","volume":"32","author":"Gu","year":"2018","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2023.04.008_b0815","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/bju.14926","article-title":"A randomized trial comparing bipolar transurethral vaporization of the prostate with GreenLight laser (xps-180watt) photoselective vaporization of the prostate for treatment of small to moderate benign prostatic obstruction: outcomes after 2 years","volume":"125","author":"Ghobrial","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0820","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1089\/end.2012.0505","article-title":"Holmium laser enucleation of the prostate versus transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Yin","year":"2013","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2023.04.008_b0825","doi-asserted-by":"crossref","first-page":"a449","DOI":"10.1136\/bmj.39575.517674.BE","article-title":"Alternative approaches to endoscopic ablation for benign enlargement of the prostate: systematic review of randomised controlled trials","volume":"337","author":"Lourenco","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2023.04.008_b0830","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1089\/end.2016.0070","article-title":"Holmium laser enucleation of the prostate in patients requiring anticoagulation","volume":"30","author":"El Tayeb","year":"2016","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2023.04.008_b0835","doi-asserted-by":"crossref","unstructured":"Sun J, et al. Safety and feasibility study of holmium laser enucleation of the prostate (HOLEP) on patients receiving dual antiplatelet therapy (DAPT). World J Urol 2018;36:271\u2013.","DOI":"10.1007\/s00345-017-2129-y"},{"key":"10.1016\/j.eururo.2023.04.008_b0840","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1089\/end.2020.0141","article-title":"Impact on sexual function of endoscopic enucleation vs transurethral resection of the prostate for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and meta-analysis","volume":"34","author":"Liu","year":"2020","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2023.04.008_b0845","doi-asserted-by":"crossref","first-page":"427","DOI":"10.23736\/S0393-2249.19.03588-4","article-title":"Anterograde ejaculation preservation after endoscopic treatments in patients with bladder outlet obstruction: systematic review and pooled-analysis of randomized clinical trials","volume":"71","author":"Cacciamani","year":"2019","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.eururo.2023.04.008_b0850","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/ijir.2014.22","article-title":"Pilot study of the clinical efficacy of ejaculatory hood sparing technique for ejaculation preservation in Holmium laser enucleation of the prostate","volume":"27","author":"Kim","year":"2015","journal-title":"Int J Impot Res"},{"key":"10.1016\/j.eururo.2023.04.008_b0855","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.euf.2021.03.024","article-title":"Holmium versus thulium laser enucleation of the prostate: a systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Hartung","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2023.04.008_b0860","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/j.urology.2011.12.018","article-title":"Thulium laser versus holmium laser transurethral enucleation of the prostate: 18-month follow-up data of a single center","volume":"79","author":"Zhang","year":"2012","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0865","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1016\/j.juro.2011.07.073","article-title":"Thulium:YAG vapoenucleation in large volume prostates","volume":"186","author":"Bach","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0870","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1159\/000336874","article-title":"Thulium laser (Revolix) vapoenucleation of the prostate is a safe procedure in patients with an increased risk of hemorrhage","volume":"88","author":"Hauser","year":"2012","journal-title":"Urol Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0875","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s00345-013-1093-4","article-title":"Safety and effectiveness of thulium vapoenucleation of the prostate (ThuVEP) in patients on anticoagulant therapy","volume":"32","author":"Netsch","year":"2014","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0880","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1089\/end.2011.0173","article-title":"Comparison of 120\u2013200 W 2 \u03bcm thulium:yttrium-aluminum-garnet vapoenucleation of the prostate","volume":"26","author":"Netsch","year":"2012","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2023.04.008_b0885","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1089\/end.2019.0341","article-title":"Comparison of diode laser (980 nm) enucleation vs holmium laser enucleation of the prostate for the treatment of benign prostatic hyperplasia: a randomized controlled trial with 12-month follow-up","volume":"33","author":"He","year":"2019","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2023.04.008_b0890","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/bju.13255","article-title":"'Button type' bipolar plasma vaporisation of the prostate compared with standard transurethral resection: A systematic review and meta-analysis of short-term outcome studies","volume":"117","author":"Wroclawski","year":"2016","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0895","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1464-410X.2006.06683.x","article-title":"The long-term results of transurethral vaporization of the prostate using plasmakinetic energy","volume":"99","author":"Kaya","year":"2007","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0900","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.eururo.2012.04.051","article-title":"Photoselective vaporisation of the prostate using 80-W and 120-W laser versus transurethral resection of the prostate for benign prostatic hyperplasia: a systematic review with meta-analysis from 2002 to 2012","volume":"62","author":"Thangasamy","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0905","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.juro.2012.02.2576","article-title":"Holmium laser enucleation versus photoselective vaporization for prostatic adenoma greater than 60 ml: preliminary results of a prospective, randomized clinical trial","volume":"188","author":"Elmansy","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0910","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s10103-016-1895-x","article-title":"Greenlight high-performance system (HPS) 120-W laser vaporization versus transurethral resection of the prostate for the treatment of benign prostatic hyperplasia: a meta-analysis of the published results of randomized controlled trials","volume":"31","author":"Zhou","year":"2016","journal-title":"Lasers Med Sci"},{"key":"10.1016\/j.eururo.2023.04.008_b0915","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.eururo.2015.07.054","article-title":"A multicenter randomized noninferiority trial comparing GreenLight-XPS laser vaporization of the prostate and transurethral resection of the prostate for the treatment of benign prostatic obstruction: two-yr outcomes of the GOLIATH study","volume":"69","author":"Thomas","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0920","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.eururo.2010.05.026","article-title":"GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up","volume":"58","author":"Al-Ansari","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0925","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.juro.2011.04.068","article-title":"Outcomes and complications after 532 nm laser prostatectomy in anticoagulated patients with benign prostatic hyperplasia","volume":"186","author":"Chung","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0930","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/01.ju.0000146631.14200.d4","article-title":"High power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate in 66 high risk patients","volume":"173","author":"Reich","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0935","doi-asserted-by":"crossref","unstructured":"Ruszat R, et al. Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol 2007;51:1031\u20138; discussion 1038\u201341.","DOI":"10.1016\/j.eururo.2006.08.006"},{"key":"10.1016\/j.eururo.2023.04.008_b0940","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1089\/end.2005.19.1196","article-title":"Photoselective laser vaporization prostatectomy in men receiving anticoagulants","volume":"19","author":"Sandhu","year":"2005","journal-title":"J Endourol"},{"key":"10.1016\/j.eururo.2023.04.008_b0945","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.urology.2007.09.017","article-title":"Photoselective potassium titanyl phosphate (KTP) laser vaporization versus transurethral resection of the prostate for prostates larger than 70 mL: a short-term prospective randomized trial","volume":"71","author":"Horasanli","year":"2008","journal-title":"Urology"},{"key":"10.1016\/j.eururo.2023.04.008_b0950","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2011.10.009","article-title":"Laser treatment of benign prostatic obstruction: basics and physical differences","volume":"61","author":"Bach","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0955","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.juro.2017.12.065","article-title":"WATER: a double-blind, randomized, controlled trial of aquablation vs transurethral resection of the prostate in benign prostatic hyperplasia","volume":"199","author":"Gilling","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0960","first-page":"9317","article-title":"Aquablation versus transurethral resection of the prostate: 1 year United States - cohort outcomes","volume":"25","author":"Kasivisvanathan","year":"2018","journal-title":"Can J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0965","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1111\/bju.14426","article-title":"Symptom relief and anejaculation after aquablation or transurethral resection of the prostate: subgroup analysis from a blinded randomized trial","volume":"123","author":"Plante","year":"2019","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2023.04.008_b0970","first-page":"10072","article-title":"Three-year outcomes after Aquablation therapy compared to TURP: results from a blinded randomized trial","volume":"27","author":"Gilling","year":"2020","journal-title":"Can J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0975","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00345-019-02959-5","article-title":"Efficacy and safety of aquablation of the prostate for patients with symptomatic benign prostatic enlargement: a systematic review","volume":"38","author":"Suarez-Ibarrola","year":"2020","journal-title":"World J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b0980","doi-asserted-by":"crossref","first-page":"k2338","DOI":"10.1136\/bmj.k2338","article-title":"Comparison of prostatic artery embolisation (PAE) versus transurethral resection of the prostate (TURP) for benign prostatic hyperplasia: randomised, open label, non-inferiority trial","volume":"361","author":"Abt","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.eururo.2023.04.008_b0985","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1148\/radiol.2019181524","article-title":"Effectiveness of contrast-enhanced MR angiography for visualization of the prostatic artery prior to prostatic arterial embolization","volume":"291","author":"Zhang","year":"2019","journal-title":"Radiology"},{"key":"10.1016\/j.eururo.2023.04.008_b0990","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.euf.2018.09.005","article-title":"Prostatic artery embolization versus standard surgical treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis","volume":"5","author":"Zumstein","year":"2019","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.eururo.2023.04.008_b0995","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00270-020-02657-5","article-title":"Systematic review and meta-analysis comparing prostatic artery embolization to gold-standard transurethral resection of the prostate for benign prostatic hyperplasia","volume":"44","author":"Knight","year":"2021","journal-title":"Cardiovasc Intervent Radiol"},{"key":"10.1016\/j.eururo.2023.04.008_b1000","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.euros.2020.05.001","article-title":"A systematic review and meta-analysis of prostatic urethral lift for male lower urinary tract symptoms secondary to benign prostatic hyperplasia","volume":"19","author":"Xiang","year":"2020","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.eururo.2023.04.008_b1005","unstructured":"National Institute for Health and Care Excellence. Prostate artery embolisation for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE guidelines. 2018."},{"key":"10.1016\/j.eururo.2023.04.008_b1010","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jsxm.2016.03.372","article-title":"Erectile and ejaculatory function preserved with convective water vapor energy treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: randomized controlled study","volume":"13","author":"McVary","year":"2016","journal-title":"J Sex Med"},{"key":"10.1016\/j.eururo.2023.04.008_b1015","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.juro.2016.12.045","article-title":"Convective thermal therapy: durable 2-year results of randomized controlled and prospective crossover studies for treatment of lower urinary tract symptoms due to benign prostatic hyperplasia","volume":"197","author":"Roehrborn","year":"2017","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b1020","first-page":"CD012832","article-title":"Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia","volume":"2019","author":"Jung","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.eururo.2023.04.008_b1025","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/j.juro.2013.05.116","article-title":"The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. study","volume":"190","author":"Roehrborn","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b1030","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.eururo.2014.10.031","article-title":"Prostatic urethral lift improves urinary symptoms and flow while preserving sexual function for men with benign prostatic hyperplasia: a systematic review and meta-analysis","volume":"67","author":"Perera","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b1035","first-page":"7772","article-title":"Three year results of the prostatic urethral L.I.F.T. study","volume":"22","author":"Roehrborn","year":"2015","journal-title":"Can J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b1040","first-page":"8802","article-title":"Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study","volume":"24","author":"Roehrborn","year":"2017","journal-title":"Can J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b1045","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nrurol.2015.169","article-title":"New intraprostatic injectables and prostatic urethral lift for male LUTS","volume":"12","author":"Magistro","year":"2015","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b1050","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.eururo.2012.10.005","article-title":"A randomized double-blind placebo-controlled phase 2 dose-ranging study of onabotulinumtoxinA in men with benign prostatic hyperplasia","volume":"63","author":"Marberger","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b1055","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.juro.2014.02.004","article-title":"A multicenter, randomized, double-blind, placebo controlled study of onabotulinumtoxinA 200 U to treat lower urinary tract symptoms in men with benign prostatic hyperplasia","volume":"192","author":"McVary","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b1060","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/2090598X.2019.1662214","article-title":"Transperineal intraprostatic injection of botulinum neurotoxin A vs transurethral resection of prostate for management of lower urinary tract symptoms secondary to benign prostate hyperplasia: A prospective randomised study","volume":"17","author":"El-Dakhakhny","year":"2019","journal-title":"Arab J Urol"},{"key":"10.1016\/j.eururo.2023.04.008_b1065","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.urology.2020.12.022","article-title":"The iTind temporarily implanted nitinol device for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a multicenter, randomized, controlled trial","volume":"153","author":"Chughtai","year":"2021","journal-title":"Urology"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283823027318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283823027318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T13:13:35Z","timestamp":1759583615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283823027318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":213,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S0302283823027318"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2023.04.008","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Summary Paper on the 2023 European Association of Urology Guidelines on the Management of Non-neurogenic Male Lower Urinary Tract Symptoms","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2023.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}